Select Page

Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
“Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James).”

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer
“In the phase 3 TROPION-Lung01 study (NCT04656652), datopotamab deruxtecan (Dato-DXd; DS-1062a), a Trop-2 directed antibody drug conjugate (ADC), induced a statistically significant improvement in progression-free survival (PFS) when given as a treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, patients with squamous histology did not experience a benefit.”

FAPI-PET shows promise in patients with lung cancer
“FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of Nuclear Medicine.”

FOXP3: A Player of Immunogenetic Architecture in Lung Cancer
“The transcription factor forkhead box protein 3 (FOXP3) is considered to be a prominent component of the immune system expressed in regulatory T cells (Tregs). Tregs are immunosuppressive cells that regulate immune homeostasis and self-tolerance. FOXP3 was originally thought to be a Tregs-specific molecule, but recent studies have pinpointed that FOXP3 is expressed in a diversity of benign tumors and carcinomas. The vast majority of the data have shown that FOXP3 is correlated with an unfavorable prognosis, although there are some reports indicating the opposite function of this molecule. Here, we review recent progress in understanding the FOXP3 role in the immunogenetic architecture of lung cancer, which is the leading cause of cancer-related death. We discuss the prognostic significance of tumor FOXP3 expression, tumor-infiltrating FOXP3-lymphocytes, tumor FOXP3 in tumor microenvironments and the potential of FOXP3-targeted therapy.”

Asbestos victim’s dying words aired in wrongful death case against Buffet’s railroad
“HELENA, Mont. — Thomas Wells ran a half-marathon at age 60 and played recreational volleyball until he was 63. At 65 years old, doctors diagnosed him with mesothelioma, a rare and aggressive lung cancer linked to asbestos exposure.”

Some breast cancer patients could be at risk of another type of cancer, study reveals
“Women with breast cancer who have received chemotherapy are at an increased risk of developing lung cancer, a new study suggests. Epic Research, a health data group based in Wisconsin, found that women in this category have a 57% higher lung cancer risk than those who received radiation. In comparison to patients who received endocrine therapy, those who have undergone chemo have a 171% increase in lung cancer risk, the study found.”

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses
“We recently showed that lung tumor specific KRAS-G12C inhibition causes remodelling of the tumor immune microenvironment from cold to hot. As a result, KRAS-G12C inhibition is able to synergise with anti-PD-1 treatment, but only in tumor models that were already moderately responsive to immune checkpoint blockade at baseline.”

Research: Liquid Biopsy May Detect, Monitor Aggressive Lung Cancer
“A new lab assay developed by researchers at Fred Hutch Cancer Center could make diagnosis and treatment of small-cell lung cancer and non-small cell lung cancer easier.”

New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients
“Genialis, the RNA-biomarker company, today presented a poster on a new AI/ML classifier, Genialis™ krasID, that accurately predicts clinical benefit in a real-world cohort of patients who received sotorasib, a KRAS inhibitor currently approved for KRAS G12C non-small cell lung cancers. Genialis presented additional findings on the performance of the biomarker in predicting drug response across preclinical models and real-world clinical benefit at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 5-10, 2024.”

Bacteria in cancer unmasked
“Researchers have compiled a detailed catalogue of bacteria living in cancer metastases. Having analyzed over 4000 tumors, they shed light on the diversity of these co-inhabitants and how they might interact with cancer cells and their surroundings. For example, certain bacteria were linked to a worse response to immunotherapy. This study paves the way to a better understanding of how bacteria help or hinder cancer (therapy), and how we can use this for patients’ advantage.”

FDA Grants Fast Track Designation to PT217 in ES-SCLC
“PT217 has been granted fast track designation by the FDA for the treatment of ES-SCLC, according to Phanes Therapeutics. The process is designed to facilitate the development and speed up the review of drugs that treat serious conditions and fill unmet needs.”